Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?,Asia-Pacific Journal of Clinical Oncology

当前位置： X-MOL 学术 › Asia Pac. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with advanced hepatocellular carcinoma: Does the sequence matter?
Asia-Pacific Journal of Clinical Oncology ( IF 1.4 ) Pub Date : 2022-08-10 , DOI: 10.1111/ajco.13837
Kennedy Yao Yi Ng ₁ , Lawrence Wen Jun Wong ₁ , Andrea Jing Shi Ang ₁ , Ailica Wan Xin Lee ₂ , Desiree Shu Hui Tay ₂ , Jack Jie En Tan ₂ , Sze Huey Tan _{3,

4} , Su Pin Choo _{1,

5} , David Wai-Meng Tai _{1,

4} , Joycelyn Jie Xin Lee _{1,

4}

Affiliation

Combination therapy with immune checkpoint inhibitor (ICI) and antivascular endothelial growth factor (anti-VEGF) is currently the first line treatment for advanced hepatocellular carcinoma (aHCC). However, there are many patients who may not be able to receive combination therapy due to underlying comorbidities or resource limitations. For these patients, systemic treatment options include single agent tyrosine kinase inhibitors (TKIs) or ICI monotherapy. However, whether an optimal sequence of systemic therapy exists remains unknown. We aim to explore the impact of sequencing of TKI and ICI therapy in terms of response rates and to examine the safety of their use in sequential order.

中文翻译：

免疫检查点抑制剂和酪氨酸激酶抑制剂治疗晚期肝细胞癌：顺序重要吗？

免疫检查点抑制剂（ICI）和抗血管内皮生长因子（抗VEGF）的联合治疗是目前晚期肝细胞癌（aHCC）的一线治疗方法。然而，由于潜在的合并症或资源限制，许多患者可能无法接受联合治疗。对于这些患者，全身治疗选择包括单药酪氨酸激酶抑制剂 (TKI) 或 ICI 单一疗法。然而，是否存在最佳的全身治疗顺序仍然未知。我们的目的是探讨 TKI 和 ICI 疗法排序对缓解率的影响，并检查按顺序使用它们的安全性。

更新日期：2022-08-10

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11